Cancer

OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer

BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to…

2 years ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab…

2 years ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or…

2 years ago

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

2 years ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…

2 years ago

Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

2 years ago

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical…

2 years ago

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination…

2 years ago

Full-Body MRI Innovator Ezra and Longhorn Imaging Partner to Bring Full-Body MRI to Central Texas

Early cancer detection technology now available for the first time for all Central Texas area residentsNEW YORK, July 25, 2024…

2 years ago

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will…

2 years ago